CTNM

MKT CAP:$463M

Contineum Therapeutics, Inc. Class A Common Stock

Market Cap

$463M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$12.96+$1.57 (+13.78%)

Apr 22, 2026

Company Details

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead as...

CEO

Carmine N. Stengone

IPO Date

Apr 5, 2024

Website

www.contineum-tx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$60M

EPS (Diluted)

-$2.18

Free Cash Flow

-$56M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 5, 2026

$0EPS -$2.17

Q4 2025

Mar 5, 2026

$0EPS -$0.49

Q3 2025

Oct 30, 2025

$0EPS -$0.45

Q2 2025

Aug 5, 2025

$0EPS -$0.62

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 22	$0	-$81.0K	-$5M
Q1 23	$0	-$73.0K	-$5M
Q2 23	$50M	$50M	$39M
Q3 23	$0	$0	-$8M
Q4 23	$0	$0	-$10M
Q1 24	$0	$0	-$10M
Q2 24	$0	$0	-$11M
Q3 24	$0	$0	-$13M
Q4 24	$0	$0	$85M
Q1 25	$0	$0	-$18M
Q2 25	$0	-$79.0K	-$18M
Q3 25	$0	-$81.0K	-$15M
Q4 25	$0	-$85.0K	-$17M

Valuation

Quarter	P/S	P/E
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	7.8x	17.1x
Q4 23	7.8x	17.3x
Q1 24	7.8x	20.5x
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$4M	-$4M
Q1 23	-$5M	-$5M
Q2 23	$41M	$41M
Q3 23	-$5M	-$5M
Q4 23	-$11M	-$11M
Q1 24	-$8M	-$8M
Q2 24	-$8M	-$8M
Q3 24	-$6M	-$6M
Q4 24	-$10M	-$10M
Q1 25	-$14M	-$14M
Q2 25	-$16M	-$16M
Q3 25	-$12M	-$12M
Q4 25	-$13M	-$13M

Capital Expenditures

Quarter	CapEx
Q4 22	$0
Q1 23	$52.0K
Q2 23	$31.0K
Q3 23	$22.0K
Q4 23	$309.0K
Q1 24	$147.0K
Q2 24	$119.0K
Q3 24	$82.0K
Q4 24	$166.0K
Q1 25	$47.0K
Q2 25	$44.0K
Q3 25	$98.0K
Q4 25	$42.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 23	—	+77.6%
Q1 24	—	+94.1%
Q2 24	-100.0%	-1.1%
Q3 24	—	+60.8%
Q4 24	—	-975.8%
Q1 25	—	+82.4%
Q2 25	—	+63.6%
Q3 25	—	+15.1%
Q4 25	—	+120.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$491.0K	—
Q1 23	$494.0K	—
Q2 23	$489.0K	1.0%
Q3 23	$477.0K	—
Q4 23	$759.0K	—
Q1 24	$0	—
Q2 24	$0	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$3M	—
Q2 25	$2M	—
Q3 25	$3M	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$4M	—	$1M
Q1 23	$4M	—	$1M
Q2 23	$9M	$2M	—
Q3 23	$6M	$2M	—
Q4 23	$8M	$2M	—
Q1 24	$8M	$2M	—
Q2 24	$8M	$3M	—
Q3 24	$10M	$3M	—
Q4 24	$13M	$4M	—
Q1 25	$14M	$4M	—
Q2 25	$14M	$4M	—
Q3 25	$11M	—	$4M
Q4 25	$13M	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$6M	$42M	$47M
Q1 23	$0	$94M	$94M
Q3 23	$18M	$118M	$135M
Q4 23	$16M	$110M	$125M
Q1 24	$16M	$102M	$118M
Q2 24	$77M	$141M	$219M
Q3 24	$41M	$173M	$214M
Q4 24	$22M	$183M	$205M
Q1 25	$22M	$168M	$191M
Q2 25	$21M	$155M	$175M
Q3 25	$43M	$140M	$182M
Q4 25	$76M	$187M	$263M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 22	25M	—	—
Q1 23	26M	+2.4%	—
Q2 23	26M	0.0%	—
Q3 23	25M	-1.2%	—
Q4 23	25M	-1.2%	0.0%
Q1 24	26M	+2.4%	0.0%
Q2 24	26M	0.0%	0.0%
Q3 24	26M	+0.0%	+1.2%
Q4 24	26M	+0.5%	+2.9%
Q1 25	26M	+0.1%	+0.6%
Q2 25	26M	+0.1%	+0.7%
Q3 25	28M	+8.6%	+9.3%
Q4 25	31M	+9.8%	+19.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	41
Q1 25	$0	41
Q2 25	$0	41
Q3 25	$0	41
Q4 25	$0	51

Revenue / Employee